TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023

Rhea-AI Summary

TransMedics Group, Inc. (NASDAQ: TMDX), a leader in portable organ transplantation technology, announced its Q1 2023 financial results release scheduled for May 1, 2023, after market close. A conference call will follow at 4:30 p.m. ET. TransMedics focuses on improving organ quality and viability assessment, aiming to increase donor organ utilization for patients facing end-stage lung, heart, and liver failure. The company is headquartered in Andover, Massachusetts, and its technologies are crucial in addressing the significant need for better organ transplant solutions.

Positive

• Upcoming conference call for Q1 2023 financial results may provide insights into company performance.
• TransMedics is positioned as a leader in a growing niche of organ transplant technology.

Negative

• None.

ANDOVER, Mass., April 17, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2023 after market close on Monday, May 1, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.   

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-first-quarter-2023-financial-results-on-may-1-2023-301796541.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics release its Q1 2023 financial results?

TransMedics will release its Q1 2023 financial results on May 1, 2023, after market close.

What time is the conference call for TransMedics Q1 2023 results?

The conference call for TransMedics Q1 2023 results will start at 4:30 p.m. ET.

How can I listen to the TransMedics conference call?

Investors can listen to the conference call by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers.

What is the significance of TransMedics in organ transplantation?

TransMedics is a leader in portable organ perfusion technology, which improves the quality and viability of donor organs.